AI-generated analysis
Conquest Research's acquisition of NeuroTrials Research enhances its clinical trial site network with specialized expertise in neurology and related therapeutic areas, filling a strategic gap in Conquest’s portfolio. By integrating NeuroTrials’ extensive experience in neurological diseases such as Alzheimer’s Disease and sleep disorders, Conquest can expand its service offerings to better serve global pharmaceutical companies and biotechs focused on these high-growth sectors. The acquisition also provides Conquest with additional clinical sites and Principal Investigators, bolstering its capacity to manage complex trials across multiple therapeutic areas.
While the financial terms of the deal remain undisclosed, Harbor View Advisors served as the sole buy-side advisor for Conquest Research. This transaction likely involved a mix of equity and debt financing given Conquest’s status as a portfolio company of Reynolda Equity Partners, a private equity firm focused on healthcare investments. The integration will require careful coordination to maintain operational efficiency while leveraging NeuroTrials’ specialized capabilities.
The acquisition shifts competitive dynamics in the clinical research sector by consolidating market presence and expertise. Competitors like Clinical Research Associates (CRA) and MedPharma Solutions may face increased pressure to expand their own neurology-focused trial capabilities or risk losing clients to Conquest’s expanded network. This consolidation could also lead to a more fragmented landscape as smaller competitors are incentivized to merge or be acquired, accelerating the industry's trend towards specialization and scale.
Post-close, key risks include the integration of NeuroTrials’ operations into Conquest’s existing infrastructure, ensuring seamless collaboration between Principal Investigators from both organizations. Additionally, regulatory scrutiny in the clinical research sector is likely to increase as trials become more complex and specialized. Successful integration will require robust risk management and a focus on maintaining high standards for patient care and data integrity. However, with NeuroTrials’ established expertise in neurological diseases, Conquest can position itself for long-term growth by capitalizing on emerging opportunities in neurology research and development.
Conquest Research, LLC, an American clinical research organization (CRO), has acquired NeuroTrials Research, a US-based company specializing in neurological and psychiatric trial services. The acquisition closed on January 29, 2026.
| Acquirer: | Conquest Research, LLC (US) |
|---|
| Target: | NeuroTrials Research (US) |
|---|
| Type: | Acquisition |
|---|
| Value: | Undisclosed |
|---|
| Date closed: | January 29, 2026 |
|---|
| Buy-side advisors: | Harbor View Advisors |
|---|
| Sell-side advisors: | Not disclosed |
|---|
| Legal buy: | Not disclosed |
|---|
| Legal sell: | Not disclosed |
|---|
The deal aims to expand Conquest Research's clinical trial site network by incorporating NeuroTrials Research's expertise in neurology and psychiatric therapeutic areas. With this addition, Conquest Research will be better equipped to manage a broad range of complex neurological studies.
Conquest Research specializes in designing and conducting Phase I-III clinical trials for pharmaceutical companies, biotechnology firms, and medical device manufacturers. The company has been expanding its footprint through strategic acquisitions over the past few years. NeuroTrials Research brings specialized knowledge in areas such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Harbor View Advisors served as financial advisor to Conquest Research on this transaction. While details of financial terms were not disclosed, industry analysts expect the deal to bolster Conquest Research’s position in the competitive CRO sector by enhancing its service offerings and deepening its therapeutic expertise.